<DOC>
	<DOCNO>NCT01117987</DOCNO>
	<brief_summary>This multinational , multi center extension study . This study provide data long-term safety , tolerability , efficacy imatinib treatment severe pulmonary arterial hypertension .</brief_summary>
	<brief_title>Extension QTI571A2301 Evaluate Long-term Safety , Tolerability Efficacy Imatinib Severe Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients participate CQTI571A2301 clinical trial complete week 24 visit study protocol , include Study Completion assessments Patients withdraw CQTI571A2301 study prematurely reason related study drug relate safety issue perform Study Completion assessments Patients pulmonary capillary wedge pressure &gt; 15 mmHg time Study Completion assessment core protocol CQTI571A2301 . If pulmonary capillary wedge pressure attainable , leave atrial pressure measurement may use place . LVEF &lt; 45 % Patients thrombocytopenia , platelet count &lt; 50E9/L ( 50E3/ÂµL ) Patients uncontrolled systemic arterial hypertension , systolic &gt; 160 mmHg diastolic &gt; 90 mmHg Patients QTcF &gt; 450 m male &gt; 470 m female absence right branch bundle block ( base Visit 1 ECG require perform ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Pulmonary arterial hypertension , imatinib , 6MWD , pulmonary hypertension</keyword>
</DOC>